MariTide
Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations
Amgen, MariTide, weight loss, obesity treatment, clinical trial results
Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts
Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program
Amgen’s Horizon Acquisition Fuels Revenue Growth and Advances Obesity Drug MariTide
Amgen, Horizon Therapeutics, MariTide, obesity drug, revenue growth, pharmaceutical acquisition
Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results
Amgen, obesity asset, phase 1 results, MariTide, drug development, biotechnology, clinical trials
Amgen’s obesity drug takes the weight off and may keep it off, too, early data suggest
Obesity, MariTide, Weight Loss, Source, Amgen’s, weight off